[Federal Register Volume 63, Number 150 (Wednesday, August 5, 1998)]
[Notices]
[Page 41879]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-20869]


=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION


Issuer Delisting; Notice of Application to Withdraw From Listing 
and Registration; (ImmuCell Corporation, Common Stock, $.10 Par Value; 
Common Stock Purchase Rights) File No. 1-12934

July 30, 1998.
    ImmuCell Corporation (``Company'') has filed an application with 
the Securities and Exchange Commission (``Commission''), pursuant to 
Section 12(d) of the Securities Exchange Act of 1934 (``Act'') and Rule 
12d2-2(d) promulgated thereunder, to withdraw the above specified 
securities (collectively ``Securities'') from listing and registration 
on the Boston Stock Exchange, Inc. (``BSE'' or ``Exchange'').
    The reasons cited in the application for withdrawing the Securities 
from listing and registration include the following:
    The Common Stock, $.10 Par Value, of the Company (``Common 
Stock''), currently is listed for trading on the Nasdaq SmallCap Market 
and the BSE. The Common Stock Purchase Rights are transferred with, and 
only with, the Common Stock and may not be separately transferred 
unless certain triggering events occur in the future.
    The Company has complied with the instructions of the BSE by filing 
with the Exchange a letter signed by the Company's President and CEO 
and the Company's Chief Financial Officer, Treasurer and Secretary 
authorizing the withdrawal of its Securities from listing on the BSE 
and setting forth in detail the reasons for the proposed withdrawal and 
the facts in support thereof.
    In making the decision to withdraw its Securities from listing and 
registration on the BSE, the Company considered the costs and expenses 
attendant on maintaining the dual listing of its Securities on the 
Nasdaq SmallCal Market and the BSE. Given the extremely low trading 
volume experiences on the BSE over the prior several years, the Company 
does not see any advantage in maintaining the dual listing of its 
Securities and believes that the costs outweigh the benefits of 
maintaining the listing on the BSE.
    By letter dated July 6, 1998, the Exchange informed the Company 
that it would not object to the withdrawal of the Company's Securities 
from listing and registration on the BSE.
    The withdrawal from listing of the Company's Securities from the 
BSE shall have no effect upon the continued listing of such Securities 
on the Nasdaq SmallCap Market.
    By reason of Section 12(g) of the Act and the rules thereunder, the 
Company shall continue to be obligated to file reports under Section 13 
of the Act with the Commission and the Nasdaq SmallCap Market.
    Any interested person may, on or before August 20, 1998, submit by 
letter to the Secretary of the Securities and Exchange Commission, 450 
Fifth Street, NW., Washington, DC 20549, facts bearing upon whether the 
application has been made in accordance with the rules of the Exchange 
and what terms, if any, should be imposed by the Commission for the 
protection of investors. The Commission, based on the information 
submitted to it, will issue an order granting the application after the 
date mentioned above, unless the Commission determines to order a 
hearing on the matter.

    For the Commission, by the Division of Market Regulation, 
pursuant to delegated authority.
Jonathan G. Katz,
Secretary.
[FR Doc. 98-20869 Filed 8-4-98; 8:45 am]
BILLING CODE 8010-01-M